Journal of Pharmacy Technology最新文献

{"title":"Beyond the Classroom: An Observational Study to Assess Student Pharmacists' Confidence and Perception of a High-Fidelity Manikin Chemotherapy Infusion Reaction Simulation.","authors":"Jeremiah K Jessee,&nbsp;Akera Miller,&nbsp;Alex M Ebied","doi":"10.1177/87551225211073570","DOIUrl":"https://doi.org/10.1177/87551225211073570","url":null,"abstract":"<p><p><b>Objective:</b> To assess the impact of a high-fidelity manikin chemotherapy infusion simulation on student pharmacists' confidence in applying clinical knowledge and perception of oncology pharmacy practice. <b>Methods:</b> One cohort of third professional year student pharmacists completed a high-fidelity manikin simulation during the last week of their didactic training. The 10-minute manikin experience simulated an acute paclitaxel infusion reaction, requiring students to apply their knowledge on how to provide patient care during a chemotherapy-induced infusion reaction. A pre- and post-survey was administered to determine whether there was a change in students' confidence and perception. <b>Results:</b> Thirty-three student pharmacists (62%) completed the pre- and post-surveys and manikin simulation. A statistically significant improvement was seen in median confidence scores when comparing pre- and post-questions of all 10 survey items (<i>P</i> < 0.001). Students' perception of oncology pharmacy and the manikin simulation had mean of 4.4 on a 0- to 5-point Likert scale. <b>Conclusion:</b> The high-fidelity manikin experience improved student pharmacists' post-survey confidence of applying clinical skills. In addition, students' perception of oncology pharmacy improved and the use of a manikin simulation to support didactic learning was seen as an additional avenue for delivering didactic curriculum. This study explored the feasibility of introducing a manikin simulation into the oncology pharmacy curriculum and the benefit of providing hands-on application of clinical skills to support didactic concept-based learning.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116123/pdf/10.1177_87551225211073570.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10610670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Indomethacin for Reducing Chest Tube Duration After Coronary Artery Bypass Grafting Surgery.","authors":"Caitlin M Gibson,&nbsp;Brenton Hall,&nbsp;Hyanggi Irene Kwon,&nbsp;Sondra Davis,&nbsp;Darien Bradford,&nbsp;Meredith L Howard","doi":"10.1177/87551225221074588","DOIUrl":"https://doi.org/10.1177/87551225221074588","url":null,"abstract":"<p><p><b>Background:</b> Nonsteroidal anti-inflammatory drugs (NSAIDs) contain a boxed warning for use in coronary artery bypass graft (CABG) surgery due to increased risk of thrombotic events, but recent research has challenged the assumption that these risks are a class effect. One anecdotal indication for NSAIDs in CABG is reducing chest tube output. <b>Objective:</b> The primary objective of this retrospective study was to determine whether indomethacin was associated with reduced duration of chest tube insertion after CABG surgery, defined as total chest tube duration in controls versus duration of chest tube insertion after the first dose of indomethacin in the treatment group. Secondary objectives were comparisons of daily reductions in chest tube output volume, length of stay, and safety between groups. <b>Methods:</b> In this retrospective, single-center case-control review, adult patients who received indomethacin after CABG were matched 1:1 to control patients based on age, sex, concomitant valve surgery, and, when possible, diabetes status. <b>Results:</b> Thirty-two patients were included. The mean age was 56 years and 75% were men. The primary outcome measure was 94 hours among control patients and 82.8 hours among indomethacin patients (<i>P</i> = 0.041). Insignificant mean reductions in daily chest tube output were observed prior to and after indomethacin initiation (38.7 vs 87.7 mL/day, <i>P</i> > 0.05). <b>Conclusion:</b> In this small, single-center study, indomethacin appeared safe and possibly effective for reducing chest tube duration after CABG surgery. Future large, prospective, randomized studies should be conducted to confirm the results.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116119/pdf/10.1177_87551225221074588.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10306023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seizures Associated With Bone Density Conservation Agents.","authors":"Kuan Sturgill,&nbsp;Justin P Reinert","doi":"10.1177/87551225211070978","DOIUrl":"https://doi.org/10.1177/87551225211070978","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this review is to discuss the existing literature regarding patients who have experienced seizures after administration of a bone density conservation agent (BDCA).</p><p><strong>Data sources: </strong>A comprehensive literature review was performed between September and October 2021 using the following keywords: osteoporosis/drug therapy, seizures/chemically induced, hypercalcemia, hypocalcemia, osteoporosis, seizure risk, osteoclast medication, seizures, bisphosphonates, risedronate, zoledronic acid, pamidronate, denosumab, Prolia, Xgeva, calcitonin, BDCAs.</p><p><strong>Study selection and data extraction: </strong>A total of 90 articles were identified, but only 6 articles met prespecified inclusion and exclusion criteria. These articles included 4 case reports, 1 case series, and 1 retrospective cohort study.</p><p><strong>Data synthesis: </strong>Two case reports and 1 case series described the occurrence of seizures with the use of zoledronic acid. One case report described the occurrence of seizures with the use of alendronate, 1 retrospective cohort study with the use of denosumab, and 1 case report with the use of calcitonin. The articles displayed a variety of contributing factors that could have caused seizures including those with a prior history of seizures, calcium or vitamin D deficiency prior to starting therapy, a history of gastrectomy impairing glucose homeostasis, or concurrent infection.</p><p><strong>Conclusion: </strong>While there is not a direct link to BDCA causing seizures, the hypocalcemic effect may be severe enough in some patients to precipitate a seizure. The correction of underlying conditions and electrolyte disturbances should be addressed before initiating a BDCA. Further studies are needed to better explore the relationship between BDCA and seizures.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096843/pdf/10.1177_87551225211070978.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Miconazole Cream and Warfarin Interaction: A Case Report.","authors":"Taylor Naberhaus,&nbsp;Maura J Jones,&nbsp;Andrea Burns,&nbsp;Erin C Raney","doi":"10.1177/87551225211069490","DOIUrl":"https://doi.org/10.1177/87551225211069490","url":null,"abstract":"Warfarin is noted for many drug and food interactions, particularly those involving Cytochrome P450 (CYP) metabolism.1 We present a case to document a probable interaction between warfarin and topical miconazole cream in an older adult male. An 85-year-old male prescribed warfarin for a history of recurrent deep vein thromboses was managed by a team of clinical pharmacists via collaborative practice agreement in a family medicine clinic for 11 years. His international normalized ratio (INR) goal was 2.5 (2.0-3.0). His INR was monitored monthly, and his weekly warfarin dose of 25 mg was stable for the 3 months prior to initiation of topical miconazole. The patient also received home hospice services with qualifying diagnoses of senile degeneration of brain and muscle weakness. Additional comorbidities included type 2 diabetes, hypertension, coronary artery disease, and chronic kidney disease. Other chronic medications included hydroxyzine, insulin lispro, insulin glargine, lovastatin, topical Neosporin® (neomycin-bacitracinpolymyxin) ointment, lidocaine 4% cream, vitamin-D3, and amlodipine. After developing a large rash and sore to his buttocks and hips of fungal origin, Baza® Antifungal Cream (miconazole nitrate 2%) was prescribed for once daily application per the hospice team without the family medicine provider’s awareness. After 2 weeks of once daily application, the frequency was increased to 3 times daily, occurring approximately 2 weeks prior to the next routinely scheduled INR. That routinely scheduled INR was 10.0. The patient’s wife denied any changes in appetite, vitamin K intake or other foods known to affect warfarin, alcohol intake, warfarin dose, or other medications. The patient was hospitalized, where his subsequent INR was 14.1. He displayed swelling and ecchymosis in his left hand from recent injury, but denied melena, epistaxis, and hematuria with a hemoglobin of 12.2 g/dL. He received 4 units of fresh frozen plasma and 5 mg intravenous vitamin K, correcting the INR to 1.2. Miconazole cream was discontinued. The patient’s warfarin dose was adjusted as shown in Table 1 and titrated to his previously stable dose within 1 month. Miconazole is an imidazole antifungal agent and CYP2C9 inhibitor. Miconazole oral and vaginal formulations are known to increase warfarin response.1-3 There is 1 documented case of topical miconazole cream interacting with warfarin in an 80-year-old male when applied to the groin resulting in an INR of 21.4.4 Two reports of econazole topical cream, also applied to the groin area of a 51-year-old male and a 79-year-old male with previously stable INRs, resulted in INRs of greater than 9.0 and 12.0, respectively.5,6 Of note, the recommended twice daily application of miconazole topical cream was exceeded in this case, possibly increasing the risk of this interaction.7 A Drug Interaction Probability Scale (DIPS) was completed, with a score of 7 (Table 2). This represents a probable drug interaction between m","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096844/pdf/10.1177_87551225211069490.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10562131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists' Perspectives on the Use of Telepharmacy in Response to COVID-19 Pandemic in Ho Chi Minh City, Vietnam.","authors":"Truong Van Dat,&nbsp;Trung Dinh Tran,&nbsp;Nguyen Thao My,&nbsp;Tran Thi Hong Nguyen,&nbsp;Nguyen Nhat Anh Quang,&nbsp;Mi Tra Vo Nguyen,&nbsp;Phuc Hong Ngoc Vo,&nbsp;Thanh-Tam Ho,&nbsp;Cuong Manh Nguyen,&nbsp;Tram Thi Ngoc Nguyen,&nbsp;Nguyen-Huu Lac-Thuy,&nbsp;Nga Tq Nguyen,&nbsp;Dieu-Thuong Thi Trinh,&nbsp;Hai-Yen Nguyen-Thi,&nbsp;Nguyen Tien Huy","doi":"10.1177/87551225221076327","DOIUrl":"https://doi.org/10.1177/87551225221076327","url":null,"abstract":"<p><p><b>Introduction:</b> Telepharmacy, the application of information and communication technologies in healthcare services, has been adopted in many countries to provide patients with pharmaceutical care. However, it has yet to be widely used in Vietnam. This study was conducted to assess the current status of use and the factors associated with the willingness to use telepharmacy of pharmacists in Vietnam. <b>Methods:</b> A descriptive cross-sectional study was conducted from February to July 2021; 414 pharmacists were recruited to fill in an online survey. <b>Results:</b> Overall, 86.7% of participants have used telepharmacy application and 87.2% of them were willing to apply telepharmacy in pharmacy practice. According to our multivariate analysis, the level of readiness was associated with positive attitude (odds ratio [OR] = 4.67; 95% confidence interval [CI]: 2.26-9.66), and a good behavior (OR = 11.34; 95% CI: 3.84-33.45). <b>Discussion:</b> Developing a telepharmacy system with appropriate features is essential to meet the requirements of pharmacy practice amid the spread of the COVID-19 pandemic.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096850/pdf/10.1177_87551225221076327.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10830341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considerations When Transitioning From Health-System Pharmacy Administration and Leadership Resident to Pharmacy Leader.","authors":"Tyler A Vest,&nbsp;Lindsey B Amerine","doi":"10.1177/87551225211051938","DOIUrl":"https://doi.org/10.1177/87551225211051938","url":null,"abstract":"<p><p>A key part to assimilating into an organization in a leadership role is managing transitions. Health-System Pharmacy Administration and Leadership (HSPAL) Residency Programs focus on laying the foundation for continued growth in management and leadership skills. This article focuses on keys for transitioning from HSPAL Pharmacy Resident to Pharmacy Leader. Managing transitions is and will continue to be an important topic for all leaders. As HSPAL Residents transition to new pharmacy leaders, understanding pharmacy practice building relationships, maintaining them, and having a thoughtful strategy through this transition will allow for a more complete understanding of the organization to navigate complexities, develop people, and complete projects and initiatives. While this article is specific to HSPAL residents, these concepts can apply to the transition to pharmacy leaders.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096846/pdf/10.1177_87551225211051938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10736536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large Statewide Health System During the Pandemic in 2020.","authors":"Jonathan H Watanabe,&nbsp;Jimmy Kwon,&nbsp;Bin Nan,&nbsp;Shira R Abeles,&nbsp;Sanjay R Mehta","doi":"10.1177/87551225211068675","DOIUrl":"https://doi.org/10.1177/87551225211068675","url":null,"abstract":"<p><p><b>Background:</b> Understanding medication use patterns for patients with COVID-19 will provide needed insight into the evolution of COVID-19 treatment over the course of the SARS-CoV-2 pandemic and aid clinical management considerations. <b>Objectives:</b> To systematically determine most frequently used medications among COVID-19 patients overall and by hospitalization status. Secondary objective was use measurement of medications considered potential therapeutic options. <b>Methods:</b> Retrospective cohort study was performed using data from the University of California COVID Research Data Set (UC CORDS) patients between March 10, 2020, and December 31, 2020. Main outcomes were percentages of patients prescribed medications, overall, by age group, and by comorbidity based on hospitalization status for COVID-19 patients. Use percentage by month of COVID-19 diagnosis was measured. Cumulative count of potential therapeutic options was measured over time. <b>Results:</b> Dataset included 22 896 unique patients with COVID-19 (mean [SD] age, 42.4 [20.4] years; 12 154 [53%] women). Most frequently used medications in patients overall were acetaminophen (21.2%), albuterol (14.9%), ondansetron (13.9%), and enoxaparin (10.8%). Dexamethasone use increased from fewer than 50 total hospitalized patients through April who had received the medication, to more than 500 patients by mid-August. Cumulative count of enoxaparin users was the largest throughout the study period. <b>Conclusion and Relevance:</b> In this retrospective cohort study, across age and comorbidity groups, predominant utilization was for supportive care therapy. Dexamethasone and remdesivir experienced large increases in use. Conversely, hydroxychloroquine and azithromycin use markedly dropped. Medication utilization rapidly shifted toward more evidence-concordant treatment of patients with COVID-19 as rigorous study findings emerged.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096847/pdf/10.1177_87551225211068675.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10637063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Dispense Tracking Software on Inpatient Pharmacy Operations.","authors":"Zachariah Gunter, Nikolaus Lawson, Carolyn Bondarenka","doi":"10.1177/87551225211069001","DOIUrl":"10.1177/87551225211069001","url":null,"abstract":"<p><p><b>Background:</b> When medications dispensed from a hospital inpatient pharmacy aren't able to be found at their intended destination (ie, a missing dose), this can result in delayed medication administration and rework to redispense the medication. Technology advancements in the medication use process have led to development of dose-tracking software that has the capability to track medication doses throughout the medication use cycle and document a medication's location to its destination. <b>Objective:</b> The primary objective of this study was to evaluate the impact of dose-tracking software on the number of inpatient pharmacy redispenses and nursing requests for missing medications. Secondary objectives included pharmacy staff satisfaction with dose-tracking software, its impact on workflow and patient safety, and compliance with dose-track scanning. <b>Methods:</b> The study design was a prospective, pre-post implementation to compare the requests for missing doses and associated dispenses of injectable medications during the set evaluation period. Dose-track scanning compliance data was collected and evaluated. A survey was also administered to staff to evaluate employee perception and satisfaction with usability and value of the software. <b>Results:</b> During the preimplementation period, 40 021 injectable doses were dispensed, and 9841 (24.6%) were documented as redispensed doses. After dose-tracking implementation, 42 975 total injectable doses were dispensed with 9839 (22.9%) being redispensed. The count of medication messages was 10 661 in the preperiod and 11 475 in the postperiod. The data were normalized using case mix index (CMI) and patient days to account for variation in severity of illness. <b>Conclusion:</b> Implementation of dose-tracking software showed a decrease in the percentage of redispensed injectable medications.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096849/pdf/10.1177_87551225211069001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9110518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of SGLT2 Inhibitor Therapy and Other Potential Risk Factors for the Development of Bacteremia in Patients With Urosepsis.","authors":"Elizabeth W Covington,&nbsp;Kelly Slaten,&nbsp;Adam Harnden","doi":"10.1177/87551225221074578","DOIUrl":"https://doi.org/10.1177/87551225221074578","url":null,"abstract":"<p><p><b>Background:</b> Risk factors for the development of bacteremia in patients with urosepsis are not well-defined in the current literature. <b>Objective:</b> To assess potential risk factors, including receipt of SGLT2 inhibitor therapy (SGLT2-I), for the development of bacteremia in patients with urosepsis. <b>Methods:</b> A retrospective case control study was performed on patients admitted to a community hospital. Patients were included if they had a positive urine culture and met criteria for urosepsis. Exclusion criteria included proven source of infection outside of the urogenital tract, age less than or equal to 18 years old, and pregnancy. Included patients were placed into 1 of 2 groups: bacteremia or non-bacteremia. The primary endpoint was the percentage of patients taking an SGLT2-I in the bacteremia versus the non-bacteremia group. Secondary endpoints included an assessment of potential risk factors for the development of bacteremia in patients with urosepsis via univariate and multivariate regression analysis and comparison of clinical outcomes in patients receiving SGLT2-I prior to admission versus those not receiving SGLT2-I. <b>Results:</b> There was no difference in the proportion of patients within the bacteremia and non-bacteremia groups who were receiving an SGLT2-I (12% vs. 19%, <i>P</i> = 0.277). Binary multivariate regression analysis identified 2 variables associated with increased risk of bacteremia: male gender and cirrhosis. <b>Conclusion:</b> Within this study, there was no difference in the proportion of patients receiving an SGLT2-I in bacteremia and non-bacteremia groups. Potential risk factors for the development of bacteremia identified included male gender and cirrhosis. However, results from our study should be confirmed in larger scale studies.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096848/pdf/10.1177_87551225221074578.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10629616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist Hypertension Management Quality Review at an Ambulatory Care Clinic.","authors":"Kayla Chonko,&nbsp;Sandra Axtell,&nbsp;Bianca Mayzel","doi":"10.1177/87551225211064240","DOIUrl":"https://doi.org/10.1177/87551225211064240","url":null,"abstract":"<p><p><b>Background:</b> A reduction of 10 mm Hg in systolic blood pressure (SBP) significantly decreases the risk of major cardiovascular disease events. Pharmacists' management of blood pressure may assist with this reduction. <b>Objective:</b> Assess the impact of pharmacist management of hypertension via a collaborative practice agreement with physicians in an ambulatory care clinic. <b>Methods:</b> The first phase of this study was a retrospective chart review of physician/nurse hypertension visits from October 2019 to August 2020. The second prospective phase consisted of pharmacist managed hypertension visits from December 2020 to January 2021. The primary outcome was the change in SBP from the beginning to the end of the study period in the prospective group. Secondary outcomes included the proportion of patients achieving their blood pressure goal and the proportion of patients adherent to all antihypertensive medications at their follow-up visits in both groups. This study was institutional review board approved. <b>Results:</b> Forty-seven patients were included and analyzed (24 in the retrospective group and 23 in the prospective group). Patients in the prospective group had an average SBP lowering of 10.83 mm Hg (<i>P</i> = .0035). Thirteen patients (56.5%) met their blood pressure goal of <130/80 mm Hg in the prospective group, compared to 5 patients (20.8%) in the retrospective group (<i>P</i> = .012). One adverse event occurred during this study. Limitations included small sample size and short duration of study. <b>Conclusion:</b> Patients had an average SBP lowering of >10 mm Hg. More patients reached a goal blood pressure of <130/80 mm Hg when managed by pharmacists.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820044/pdf/10.1177_87551225211064240.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10407960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}